Transaction · 0001193125-26-395837

Vieira Roberto Wandenkolk

Vieira Roberto Wandenkolk, PRES, reported an open-market or private sale at CORCEPT THERAPEUTICS INC involving 296.000000 shares for an estimated $29842.72. Reported holdings after the transaction were 3946.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES
CORTCORCEPT THERAPEUTICS INC
Trade date
Sep 16, 2026
Filing date
Sep 18, 2026
View on SEC Insider profile
Estimated value-$29.8kShares × reported price
Shares traded296$100.82 per share
Holdings after3.94kDirect
% of reported position traded6.98%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 4,242 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CORT price since this filing

Daily closing prices, with the filing date and available return windows
CORT · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +6.2%1w ago +4.9%1d ago +0.5%
Returns since7d +5.3%30d -0.1%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-395837
Common Stock
Transaction date
Sep 16, 2026
Filed Sep 18, 2026, 11:53 PM · 2d delay
Shares
296 sh
$100.82 per share
Estimated value
-$29.8k
Computed from shares × price
Holdings after
3,946 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, Oncology

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the…

  2. F2

    Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the…

Original filing · 0001193125-26-395837
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CORT